Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 4/20 | 0.54 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.54 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21853773 | 1.00 | SLC1A1 (0.54) | SLC1A1SLC1A3SLC1A2CYP2C19MEN1 | |
| SCHEMBL8430055 | 0.91 | SLC1A1 (0.51) | SLC1A1SLC1A3SLC1A2CYP2C19MEN1 | |
| SCHEMBL8836900 | 0.91 | SLC1A1 (0.51) | SLC1A1SLC1A3SLC1A2CYP2C19MEN1 | |
| SCHEMBL8722230 | 0.84 | CYP2C19 (0.47) | SLC1A1SLC1A3SLC1A2CYP2C19MEN1 | |
| SCHEMBL8836944 | 0.84 | SLC1A1 (0.59) | SLC1A1SLC1A3SLC1A2CYP2C19MEN1 | |
| SCHEMBL8426348 | 0.84 | SLC1A1 (0.59) | SLC1A1SLC1A3SLC1A2CYP2C19MEN1 | |
| SCHEMBL27931897 | 0.84 | SLC1A1 (0.59) | SLC1A1SLC1A3SLC1A2CYP2C19MEN1 | |
| SCHEMBL6051430 | 0.82 | SLC1A1 (0.65) | SLC1A1SLC1A3SLC1A2CYP2C19MEN1 | |
| SCHEMBL6051426 | 0.82 | SLC1A1 (0.65) | SLC1A1SLC1A3SLC1A2CYP2C19MEN1 | |
| SCHEMBL27479686 | 0.82 | SLC1A1 (0.65) | SLC1A1SLC1A3SLC1A2CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| EP-3630795-B1 | ENGINEERED ALDOLASE POLYPEPTIDES AND USES THEREOF | ENZYMASTER NINGBO BIO ENG CO LTD (CN) | 2023-07-26 | — | — | EP | disclosed |
| CN-110869383-B | Engineered polypeptides and their use in the synthesis of beta-hydroxy-alpha-amino acids | 宁波酶赛生物工程有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-110914288-B | Engineered aldolase polypeptides and uses thereof | 宁波酶赛生物工程有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-11274287-B2 | Engineered aldolase polypeptides and uses thereof | Enzymaster (Ningbo) Bio-Engineering Co., Ltd (CN) | 2022-03-15 | — | — | US | disclosed |
| US-20200123525-A1 | ENGINEERED ALDOLASE POLYPEPTIDES AND USES THEREOF | Enzymaster (Ningbo) Bio-Engineering Co., Ltd (CN) | 2020-04-23 | — | — | US | disclosed |
| WO-2007002594-A1 | COSMETIC COMPOSITIONS AND METHODS USING TRANSFORMING GROWTH FACTOR-BETA MIMICS | BHATNAGAR RAJENDRA S (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002469-A2 | THERAPEUTIC COMPOSITIONS AND METHODS USING TRANSFORMING GROWTH FACTOR-BETA MIMICS | BHATNAGAR RAJENDRA S (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293228-A1 | Therapeutic compositions and methods using transforming growth factor-beta mimics | BHATNAGAR RAJENDRA S | 2006-12-28 | — | — | US | disclosed |
| US-20060293227-A1 | Cosmetic compositions and methods using transforming growth factor-beta mimics | BHATNAGAR RAJENDRA S | 2006-12-28 | — | — | US | disclosed |
| EP-1252178-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-05 | — | — | US | disclosed |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-30 | — | — | US | disclosed |
| EP-1196436-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001064678-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001040262-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001002424-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-01-11 | — | — | WO | disclosed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0787010-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996012499-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274287-B2 | Engineered aldolase polypeptides and uses thereof | DERA, ALDOA, TKT | SLC1A1 372/4885SLC1A3 390/4885SLC1A2 279/4885 |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | TMPRSS15, CTRC, CPN1 | SLC1A1 2630/4885SLC1A3 2604/4885SLC1A2 3427/4885 |
| US-20200123525-A1 | ENGINEERED ALDOLASE POLYPEPTIDES AND USES THEREOF | DERA, ALDOA, TKT | SLC1A1 372/4885SLC1A3 390/4885SLC1A2 279/4885 |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | CES1, CYP51A1, SPINT2 | SLC1A1 3301/4885SLC1A3 3020/4885SLC1A2 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.